Cover
Cover - shares | 3 Months Ended | |
Mar. 31, 2023 | May 03, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Mar. 31, 2023 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2023 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 000-32363 | |
Entity Registrant Name | CANCER CAPITAL CORP. | |
Entity Central Index Key | 0001130889 | |
Entity Tax Identification Number | 91-1803648 | |
Entity Incorporation, State or Country Code | WY | |
Entity Address, Address Line One | 2157 S. Lincoln Street | |
Entity Address, Address Line Two | Suite 200 | |
Entity Address, City or Town | Salt Lake City | |
Entity Address, State or Province | UT | |
Entity Address, Postal Zip Code | 84106 | |
City Area Code | (801) | |
Local Phone Number | 323-2395 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | false | |
Entity Shell Company | true | |
Entity Common Stock, Shares Outstanding | 6,150,000 |
Condensed Balance Sheets (Unaud
Condensed Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
CURRENT ASSETS | ||
Cash | $ 17,856 | $ 22,055 |
Total current assets | 17,856 | 22,055 |
TOTAL ASSETS | 17,856 | 22,055 |
CURRENT LIABILITIES | ||
Accounts payable – related party | 7,500 | 6,000 |
Notes payable – related party | 155,125 | 155,125 |
Notes payable | 130,275 | 130,275 |
Accrued interest – related party | 80,783 | 77,680 |
Accrued interest | 67,180 | 64,574 |
Total current liabilities | 440,863 | 433,654 |
Total liabilities | 440,863 | 433,654 |
STOCKHOLDERS' DEFICIT | ||
Common stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding | 6,150 | 6,150 |
Additional paid-in capital | 47,050 | 47,050 |
Accumulated deficit | (476,207) | (464,799) |
Total stockholders' deficit | (423,007) | (411,599) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 17,856 | $ 22,055 |
Condensed Balance Sheets (Una_2
Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Mar. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 20,000,000 | 20,000,000 |
Common Stock, Shares, Issued | 6,150,000 | 6,150,000 |
Common Stock, Shares, Outstanding | 6,150,000 | 6,150,000 |
Condensed Statements of Operati
Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Revenues | ||
Operating expenses | ||
General and administrative | 5,699 | 9,110 |
Total operating expenses | 5,699 | 9,110 |
Loss from operations | (5,699) | (9,110) |
Other expense | ||
Interest expense – related party | (3,103) | (2,902) |
Interest expense | (2,606) | (2,186) |
Total other expense | (5,709) | (5,088) |
Loss before income taxes | (11,408) | (14,198) |
Income tax expense | ||
Net loss | $ (11,408) | $ (14,198) |
Net loss per share – Basic and diluted | $ 0 | $ 0 |
Weighted average shares outstanding – Basic and diluted | 6,150,000 | 6,150,000 |
Condensed Statements of Stockho
Condensed Statements of Stockholders' Deficit (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance – December 31, 2022 at Dec. 31, 2021 | $ 6,150 | $ 47,050 | $ (422,332) | $ (369,132) |
Shares, Outstanding, Beginning Balance at Dec. 31, 2021 | 6,150,000 | |||
Net loss | (14,198) | (14,198) | ||
Balance – March 31, 2023 at Mar. 31, 2022 | $ 6,150 | 47,050 | (436,530) | (383,330) |
Shares, Outstanding, Ending Balance at Mar. 31, 2022 | 6,150,000 | |||
Balance – December 31, 2022 at Dec. 31, 2022 | $ 6,150 | 47,050 | (464,799) | (411,599) |
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 | 6,150,000 | |||
Net loss | (11,408) | (11,408) | ||
Balance – March 31, 2023 at Mar. 31, 2023 | $ 6,150 | $ 47,050 | $ (476,207) | $ (423,007) |
Shares, Outstanding, Ending Balance at Mar. 31, 2023 | 6,150,000 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Cash Flows from Operating Activities | ||
Net Loss | $ (11,408) | $ (14,198) |
Adjustment to reconcile net loss to cash used by operating activities: | ||
Expenses paid by related party | 1,500 | 1,500 |
Changes in operating assets and liabilities: | ||
Increase in accrued interest – related party | 3,103 | 2,903 |
Increase in accrued interest | 2,606 | 2,186 |
Net cash used by operating activities | (4,199) | (7,609) |
Cash Flows from Investing Activities | ||
Net cash provided by investing activities | ||
Cash Flows from Financing Activities | ||
Proceeds from notes payable | 28,000 | |
Net cash provided by financing activities | 28,000 | |
Increase (decrease) in cash | (4,199) | 20,391 |
Cash at beginning of period | 22,055 | 62 |
Cash at end of period | 17,856 | 20,453 |
Supplemental Cash Flow Information: | ||
Cash paid for interest | ||
Cash paid for income taxes |
NOTE 1 - BASIS OF FINANCIAL STA
NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION | NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION The accompanying unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim condensed financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed financial statements be read in conjunction with the Company’s audited financial statements and notes thereto included in its December 31, 2022 Annual Report on Form 10-K. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for year ending December 31, 2023. |
NOTE 2 _ GOING CONCERN
NOTE 2 – GOING CONCERN | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NOTE 2 – GOING CONCERN | NOTE 2 – GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies. |
NOTE 3 _ RELATED PARTY TRANSACT
NOTE 3 – RELATED PARTY TRANSACTIONS | 3 Months Ended |
Mar. 31, 2023 | |
Related Party Transactions [Abstract] | |
NOTE 3 – RELATED PARTY TRANSACTIONS | NOTE 3 – RELATED PARTY TRANSACTIONS During the three months ended March 31, 2023 and 2022, a shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $ 1,500 1,500 7,500 6,000 A shareholder has loaned the Company funds in prior years. The notes bear interest at 8 155,125 155,125 80,783 77,680 |
NOTE 4 _ NOTES PAYABLE
NOTE 4 – NOTES PAYABLE | 3 Months Ended |
Mar. 31, 2023 | |
Debt Disclosure [Abstract] | |
NOTE 4 – NOTES PAYABLE | NOTE 4 – NOTES PAYABLE During the three months ended March 31, 2023 and 2022, the Company was loaned $ 0 28,000 8 130,275 130,275 67,180 64,574 |
NOTE 5 _ SUBSEQUENT EVENTS
NOTE 5 – SUBSEQUENT EVENTS | 3 Months Ended |
Mar. 31, 2023 | |
Subsequent Events [Abstract] | |
NOTE 5 – SUBSEQUENT EVENTS | NOTE 5 – SUBSEQUENT EVENTS |
NOTE 3 _ RELATED PARTY TRANSA_2
NOTE 3 – RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Related Party Transactions [Abstract] | |||
Costs and Expenses, Related Party | $ 1,500 | $ 1,500 | |
[custom:AccountsPayableRelatedPartiesCurrent1-0] | $ 7,500 | $ 6,000 | |
Debt Instrument, Interest Rate During Period | 8% | 8% | |
[custom:NotesPayableRelatedPartiesClassifiedCurrent1-0] | $ 155,125 | 155,125 | |
Accrued Liabilities and Other Liabilities | $ 80,783 | $ 77,680 |
NOTE 4 _ NOTES PAYABLE (Details
NOTE 4 – NOTES PAYABLE (Details Narrative) - USD ($) | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Debt Disclosure [Abstract] | |||
Proceeds from Notes Payable | $ 28,000 | ||
Debt Instrument, Interest Rate During Period | 8% | 8% | |
Notes Payable, Current | $ 130,275 | $ 130,275 | |
Interest Payable, Current | $ 67,180 | $ 64,574 |